Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells (Q37814419)

23 August 2017

1 reference

title

Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells (English)

1 reference

23 August 2017

Stephen M Ansell

1

1 reference

PubMed ID

21121873

23 August 2017

language of work or name

English

0 references

publication date

2 December 2010

1 reference

Expert Opinion on Investigational Drugs

23 August 2017

1 reference

23 August 2017

20

1 reference

23 August 2017

1

1 reference

23 August 2017

99-105

1 reference

Expression and a role of CD30 in regulation of T-cell activity

23 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542147

Management of Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542147

Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542147

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542147

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542147

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542147

Vinorelbine: a new promising drug in Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542147

Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542147

Anaplastic Large Cell Lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542147

ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542147

ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects--a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542147

Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542147

A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542147

A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542147

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542147

Novel peptide linkers for highly potent antibody-auristatin conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542147

Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542147

Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542147

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.542147

10.1517/13543784.2011.542147

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

21121873